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Abstract 
Aims: Overactive bladder (OAB) and benign prostatic hyperplasia (BPH) are highly 
prevalent conditions that place a large burden on the United States (US) health care system. 
We sought to analyze patterns of prescription medication usage for incident OAB in men and 
women and for incident BPH in men using US health insurance claims data. 
 
Materials and Methods: This study used Truven Health MarketScan® Commercial and 
Medicare Supplemental Research databases. The data were pooled from diverse points of 
care. BPH subjects included men age 18+ with the first and last two diagnoses of BPH ≥30 
days apart and no BPH diagnosis for 1 year prior. OAB subjects included men and women 
age 18+, who were diagnosed similarly with incident OAB. The type of medication, 
medication continuation (persistence) and switching to a different medication were analyzed 
through September 30, 2013.  
 
Results: Medication persistence was much higher overall for BPH than OAB (56% vs. 
34%, respectively, p <0.0001), and was highest among men with BPH age 65+ (62%). 
Patients age 18-64 were less likely to continue medication than older adults (age 65+) for 
both BPH and OAB. 9.4% of patients in the OAB cohort and 6.9% of men with BPH 
switched from one medication to another.  
 
Conclusions: Persistence was higher with BPH than OAB medications overall, 
whereas switching rates were higher in the OAB group. The lower persistence of OAB 
medication may be due to less efficacy or tolerability. The possibility of under treatment of 
OAB also warrants future investigations. 
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urgency; Urge incontinence; Urgency Incontinence; Anticholinergic medication; Urinary 
frequency; Benign prostatic hyperplasia; Non-surgical management. 
Introduction 
Lower urinary tract symptoms (LUTS) are associated with a wide range of diagnoses 
including overactive bladder (OAB) symptoms with and without urinary incontinence, 
bladder infections, benign prostatic hyperplasia (BPH) and bladder pain syndrome. These 
symptoms are common in both men and women and studies show that they can lead to 
decreased quality of life.1,2 Approximately 1 in 5 adults report moderate to severe LUTS.2 
 OAB syndrome, a cluster of LUTS, is a common disabling condition occurring in 
both men and women and is associated with significant economic and healthcare burden. In 
2002, the terminology defining OAB underwent revision by the International Continence 
Society (ICS) to reflect that OAB is a symptom syndrome characterized primarily by 
urgency, but which also may include frequency and urgency urinary incontinence.1 
Epidemiologic studies have shown that urgency and frequency are more prevalent than 
urgency urinary incontinence.1 This emphasizes the focus on the symptomatology of this 
common disorder; it also points to the possibility of a symptom-based treatment approach, 
since the diagnosis of OAB is independent of the urodynamic diagnosis of detrusor 
overactivity.1,2 The age-specific prevalence of OAB is similar among men and women.1,2 
Despite the large socioeconomic burden of OAB, our recent work has shown that only 34% 
of women and 19% of men diagnosed with OAB are prescribed medication.3 
Men with LUTS often experience coexisting storage, voiding, and postmicturition 
symptoms, suggesting the need for urologic evaluation.4 Benign prostatic hyperplasia (BPH), 
a diagnosis made on the basis of histology, is a condition that occurs with aging. The 
prevalence of BPH increases from 25% among men 40 to 49 years of age to more than 80% 
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among men 70 to 79 years of age+.5 Approximately 25% of men over 50 have moderate-to-
severe LUTS.6 In fact, up to 60% of men with BPH take oral medication for their condition.7 
However, not all men with BPH develop LUTS and not all men with LUTS will have BPH. 
A greater percentage of men report storage symptoms (51.3%) than voiding (25.7%) or 
postmicturition (16.9%) symptoms.4 This suggests that many men with a diagnosis of BPH 
may, in fact, have OAB.  
For clinicians who treat LUTS, there have been several relevant clinical practice 
guidelines available to help guide management decisions.8 Medications play a key role in 
treating both OAB and BPH and are recommended by AUA/SUFU guidelines for most 
symptomatic patients in whom behavioral modification has failed.9,10 They are commonly 
prescribed and effective. However, we still have a poor understanding of the patterns of 
medical treatment for these conditions. Herein we sought to measure medication prescribing 
patterns, medication continuance (repeat prescriptions, persistence), and medication 
switching in both BPH and OAB. We also sought to compare patterns of treatment between 
the two conditions. 
Materials and Methods 
    This work was part of a mutual collaboration between the American Urological 
Association Data Committee and Pfizer, Inc., to better understand and characterize treatment 
patterns of BPH and OAB in the United States. The collaboration involved use of 
observational databases provided by Pfizer, Inc., in addition to AUA content experts to direct 
the analyses. Pfizer also provided statistical support. Our prior recent work addressed patterns 
of treatment for both BPH and OAB. Herein we specifically focused on medication 
prescribing patterns, including medication adherence and changing of medication.3,7. 
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Real-World Observational Database 
Anonymized real-world claims data from the Truven Health MarketScan® 
Commercial Claims and Encounters database and Medicare Supplemental Research 
Databases were analyzed.11 These databases include de-identified medical claims and 
prescription drug claims for individuals in the US with employer-sponsored health insurance, 
including individuals with Medicare supplemental coverage. The data were pooled from 
diverse points of care, including large employers, managed care organizations, hospitals, and 
public organizations, thus providing greater generalizability than single payer databases. No 
informed consent process or Institutional Review Board (IRB) approval were sought. 
Because this study used only de-identified patient records and does not involve the collection, 
use, or transmittal of individually identifiable data, IRB approval to conduct this study was 
not necessary. 
 
Study Design  
This observational study used the data from the Truven claims database from July 1, 
2008 to September 30, 2013. The following study periods were included in this observational 
study: 
The pre-index period is a fixed period of exactly 12 months with continuous 
enrollment before the index date. This period occurs sometime between July 1, 2008 and the 
first diagnosis.  
The index date is the first OAB (or first BPH) diagnosis occurred sometime between 
July 1, 2009 and June 30, 2012, with patients having at least two OAB (or BPH diagnoses. 
The first and the last OAB (or BPH) diagnoses would be at least 30 (i.e., ≥30) days apart in 
keeping with standards for establishing and confirming a diagnosis over time.  
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The follow-up post-index period lasted from the 1st diagnosis to the most recent 
claims data available, which was until September 30, 2013. Because this was a retrospective 
observational database study to use all available data, sample size calculation was not 
performed.  
 
Inclusion and Exclusion Criteria 
For OAB, the following inclusion criteria were applied: age 18+; at least two OAB 
diagnoses occurrences; with the first and last occurrences of OAB diagnosis at least 30 days 
apart (i.e., ≥30 days between two OAB occurrences) after the index date. Corresponding 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 
codes for the OAB diagnosis are listed in Appendix 1. 
 The following exclusion criteria for patients were applied: unknown gender; only one 
diagnosis occurrence or the first and last occurrences within 0-29 days of each other; the 
occurrence of the following diagnoses at any time during the study period: neurogenic 
bladder (596.54, 596.55, 344.61); multiple sclerosis (340, 341.0, 341.1, 341.8, 341.9); 
Parkinson’s disease (332.0, 332.1, 333.0, 094.82); cerebrovascular disease and personal 
history of other diseases of circulatory system (436, 435.9, 997.02, V12.59); spinal bifida 
(741, 741.0, 741.9, 756.17); spinal cord injury (952.x); radiation cystitis (595.82); paraplegia 
(344.1); paralysis (344.9); cerebral palsy (343.x); quadriplegia (344.x); urethral cancer 
(189.3); bladder cancer (188.x); prostate cancer (185); uterine or cervical cancer (179, 180, 
180.0, 180.1, 180.8, 180.9, 182, 182.0, 182.1, 182.8); vaginal cancer (184, 184.0); urethral 
diverticulum (599.2); urethral stricture (598.X); interstitial cystitis (595.1); prostatitis (601.x). 
For BPH, the following inclusion criteria for patients were applied: age 18+; with at 
least two BPH diagnoses occurrences; with the first and last occurrences (if there are at least 
two diagnoses) of BPH diagnosis at least 30 days apart (i.e., 30+ days between two BPH 
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occurrences) after the index date. The ICD-9-CM codes for the BPH diagnosis are listed in 
Appendix 1.  
The following exclusion criteria for patients were applied: females or unknown sex 
for BPH; only one occurrence of BPH diagnosis; the first and last occurrences within 0-29 
days; neurogenic bladder (596.54, 596.55, 344.61); multiple sclerosis (340, 341.0, 341.1, 
341.8, 341.9); Parkinson’s disease (332.0, 332.1, 333.0, 094.82); cerebrovascular disease and 
personal history of other diseases of circulatory system (436, 435.9, 997.02, V12.59); spinal 
bifida (741, 741.0, 741.9, 756.17); spinal cord injury (952.x); radiation cystitis (595.82); 
paraplegia (344.1); paralysis (344.9); cerebral palsy (343.x); quadriplegia (344.x); urethral 
cancer (189.3); bladder cancer (188.x); prostate cancer (185); uterine or cervical cancer (179, 
180, 180.0, 180.1, 180.8, 180.9, 182, 182.0, 182.1, 182.8); vaginal cancer (184, 184.0); 
urethral diverticulum (599.2); urethral stricture (598.X); interstitial cystitis (595.1); prostatitis 
(601.x). 
 
Outcome Measures 
We sought to analyze the proportion of patients who continued their OAB (or BPH) 
medication, the proportion who discontinued medication altogether, and the proportion who 
changed medication. Among patients who switched their OAB (or BPH) medication, we 
sought to determine which specific OAB (or BPH) medications were switched.  
Demographic characteristics were based on either the pre-index period or the index 
date. Medications were assessed during the post-index period and are listed by National Drug 
Code Directory (NDC) Codes in Appendices 2 (OAB) and 3 (BPH). The first OAB or BPH 
medication prescribed during the index period was considered to be the index medication. 
Demographics variables included the following: age, sex, race, geographic region, 
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urban/rural residence, insurance type, etc. Medications analyzed are listed in Appendix 2 
(OAB) and 3 (BPH).  
Persistence was defined as no 135+ days gap between prescriptions for the index 
medication during follow-up period. We defined discontinuation as having a ≥ 135-day gap 
between the exhaustion of days supplied for one OAB (or BPH) medication and the filling of 
the next OAB (or BPH) medication prescription. The 135 day gap was selected based on a 
preliminary analysis of gaps between two consecutive prescriptions for OAB medications 
(mean of day gap=142.33 days). Switching was defined as having a prescription claim for an 
OAB (or BPH) medication that is different from the index medication and the medication 
change occurred during 45 days after discontinuation of index OAB (or BPH) medication. 
The 45 days was selected to ensure the switching occurring not so far away from the 
discontinuation of the index medications. As a post-hoc secondary analysis, we also 
compared persistence rates between men with BPH and women with OAB using chi square 
statistics. 
 
Statistical Methods 
All statistical analyses were conducted using SAS Version 9.2 and/or 9.3 (SAS 
Institute, Cary, NC). Missing data were not imputed. Hypothesis-testing was not conducted 
since all analyses were exploratory in nature and analyses were univariate.  
For continuous variables, descriptive statistics were computed. For categorical variables, 
number and percentage were computed. We also compared persistence rates between men 
with BPH and women with OAB using chi square statistics as a post-hoc secondary analysis.  
 
Subgroup Analysis 
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Subgroup analysis was performed as pre-specified. For OAB, subgroup analysis 
included sex (men and women) and age intervals (<65 years old vs ≥65 years old). For BPH, 
subgroup analysis included age intervals (<65 years old vs ≥65 years old). Furthermore, 
subgroup analysis was conducted by stratification using post-index follow-up time-periods: 6 
to <24 months (i.e., 180 to <720 days) and 24+ months (i.e., 720+ days). 
 
 
Results 
A total of 89,994,604 patients were enrolled for some time during July 1, 2009 - June 
30, 2012 in the Truven database. Of these, 2,947,100 (3.3%) were assigned at least one 
diagnosis of OAB (Table 1) and 2,058,953 (2.3%) were assigned a diagnosis of BPH (Table 
2). A total of 160,853 patients with OAB and 171,224 patients with BPH met respective 
inclusion criteria. Average patient age in the OAB group was 61.7 years and the BPH group 
was 65.5 years (Tables 3 and 4). Women diagnosed with OAB were younger than men with a 
similar diagnosis (age 60.9 vs. 65.3). For OAB, the majority (75%) of patients had employer-
based insurance, and 47% of plans were preferred provider organizations (PPOs, Table 3). 
For BPH, 79% had employer based insurance and, of the benefit plans, 45% were PPOs. The 
largest minority of patients were located in the South (37% of OAB patients and 36% of 
BPH) followed by the North Central region (29% of OAB patients and 28% of BPH patients) 
A total of 38,909 (24.2%) patients with a new OAB diagnosis were prescribed OAB 
medication, including 31,701 women (19.7%) and 7,208 men (4.5%). In addition, 69,079 
(40.3%) of men with a new diagnosis of BPH were prescribed medication. Sixty-two percent 
of prescriptions for OAB were given to women in the younger age categories (19,783 women 
age 18-64 vs. 11,918 women age 65+), whereas prescriptions were more evenly distributed 
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by age in men with OAB (3,480, or 48.3%, of men age 18-64 vs. 3,728, or 51.7%, of men age 
65+). 
The most frequently prescribed index OAB medication in both men and women 
(33.1% of OAB prescriptions) was oxybutynin, followed by solifenacin (30.1%) and 
tolterodine (17.5%, Table 5). OAB prescribing patterns were similar in both men and women. 
In men with BPH, the alpha blocker tamsulosin was most frequently prescribed (48.5%), 
followed by 5-alpha reductase inhibitors finasteride (12.9%) and dutasteride (10.0%, Table 6) 
and other alpha blockers. 
 
Persistence of index medications was much higher overall for BPH than OAB (56.1% 
vs 33.7%, Table 7). This difference was statistically significant based on a post-hoc chi 
square analysis (p<.0001). Older men had a higher rate of continued medication usage for 
BPH than younger men (61.6% men age 65+ vs. 51.2% men 18-64). Patients age 18-64 were 
also less likely to continue medication than older adults (age 65+) with OAB, though this age 
difference was smaller than that seen in BPH. This was seen in both men (32.5% age 18-64 
continued vs. 37.8% 65+) and women (32.2% age 18-64 continued vs. 35.2% age 65+).  
Rates of switching index medication were 10% or less in all groups (Table 7), though 
rates of switching were lower in the BPH groups than in the OAB groups (6.9% vs. 9.4%). 
Switching was highest among women with OAB, particularly in the older age group (10%). 
Discussion 
Amongst several surprising findings we noted that the overall diagnosis rate of both OAB and 
BPH was extremely low. We included numerous specific symptoms to diagnose OAB, including 
urinary incontinence and urinary frequency. In addition, for men with BPH, we also included urinary 
retention as a symptom of BPH. Despite our broad inclusion criteria, overall one-time diagnosis rates 
were only 3.3% for OAB and 2.3% for BPH. The rates of diagnosis of BPH and OAB we found are 
comparable to those previously found in the Veteran’s Administration (VA) system as part of the 
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Urologic Diseases in America Project, 4,811 per 100,000 veterans with BPH (4.8%) and 2,161 per 
100,000 with urinary incontinence (including OAB, 2.2%).12 These diagnosis rates are rather low, 
given the high known prevalence rates of these conditions found in other studies.13-15 The National 
Overactive Bladder Evaluation (NOBLE) program found prevalence to be similar between men 
(16.0%) and women (16.9%).15 Our (low) incidence rate may suggest that many of the people with 
OAB or BPH symptoms do not seek care for them. Though the current study is not meant to measure 
prevalence, the discrepancy between national prevalence rates and diagnosis rates suggest under 
diagnosis of both conditions. Low rate of diagnosis for OAB and BPH are likely multifactorial. It is 
possible that patients in the cohort with symptoms are not bringing them to their providers’ attention, 
or perhaps they discuss symptoms with their provider, but the symptoms do not warrant a separate 
ICD code diagnosis. It is also possible that the physician does not address the problem (due to lack of 
time or lack of knowledge). Alternatively, patients may choose not to take medication, evne if 
bothered. It is also possible that patients with milder symptoms elect not to discuss their symptoms 
with their provider at all.  
 
A total of 38,909 (24.2%) patients with a new OAB diagnosis were prescribed OAB 
medication, including 31,701 women (19.7%) and 7,208 men (4.5%). Despite multiple 
medications on the market, the most commonly used drug was oxybutynin, possibly due to 
lower cost, better coverage of this agents on insurance plans, and prior provider experience 
with this agent. The fact that so little medication was prescribed to patients diagnosed with 
OAB symptoms suggests that providers may not be comfortable prescribing these 
medications, especially to men. Although the risk of retention from anticholinergics is 
extremely low (<1%),16 even in men with known BPH, generalists may be less likely to treat 
OAB symptoms in men because of a theoretically higher risk of retention due to the presence 
of an obstructing prostate. In the case of BPH, a larger minority (40.3%) was prescribed 
medication, either an alpha-blocker or a 5-alpha reductase inhibitor. One reason for not 
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prescribing medication in the majority of men with BPH may be that patients choose not to 
take medication for mild symptoms. Although alpha-blockers were the most popular BPH 
agents, 5-alpha reductase inhibitors were prescribed (either alone or in combination with 
alpha blockers) in 25% of men treated with medication. In fact, after tamsulosin, finasteride 
and dutasteride were the two most commonly prescribed BPH medications.  
The literature supports generally good compliance with both alpha-blockers and 5 
alpha reductase inhibitors,17 In fact, Shortridge et. al. analyzed electronic health records of 
1,807 men with LUTS/BPH and identified 4-year persistence of BPH medication to be 48%. 
There is evidence in the literature of poor compliance with anticholinergic medication for 
OAB,18 Similar to our study, Wagg et al. in the United Kingdom (UK) found that older adults 
(patients age 60+) were more likely to persist with OAB medication than those <age 60. This 
combination of better efficacy and fewer side effects of BPH, compared to OAB medications, 
likely explains the better persistence we identified. What our dataset did not capture were 
reasons for cessation of medication. We assume that cessation of medication may be due to 
poor efficacy and/or intolerable side effects. However, it may be that, at least in some 
patients, symptoms of OAB remit and patients no longer need medication.19  
Among men with a diagnosis of BPH in this study, persistence was higher among 
men age 65+ than among younger men. This might be due to the fact that BPH symptoms 
worsen over time, so older men are more compliant in order to maintain symptom control. It 
may also be possible that men become more compliant with medication as they age. The rate 
of medication switching was low for both OAB and BPH, yet suggests that patients are more 
likely to stop medication altogether than switch. The fact that switching was slightly higher in 
the OAB group is consistent with the higher discontinuation rate in this group. Patients who 
are unsatisfied (either from poor efficacy or poor tolerability) may be more likely to stop a 
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medication and try a new one. Also, there are more OAB medications on the market, likely 
leading to more switching between medication options. 
Limitations common to observational studies involving Electronic Health Records 
(EHR) data also apply to this study, including problems with missing data. We relied on 
diagnosis codes, which do not reflect symptom severity, and may not always be accurate. 
Also, our means to define discontinuation and switching may not accurately reflect true 
patterns of medication usage. Many patients try samples of a medication without receiving a 
prescription. We also could not differentiate between short-acting vs. long-acting 
formulations of OAB medications and we lacked information on the time of day medications 
were prescribed. Both of these factors could affect persistence rates. Because this study uses 
data from the Truven claims database only, the results may not be generalized to all patients 
with OAB or BPH. Nonetheless, the patterns of care elucidated here identify areas where 
improvement of care is needed in the care of patients, men in particular, with OAB. Despite 
the low rate of retention when anticholinergics are given to men with BPH,20 there remains a 
lack of anticholinergic prescribing for this population. 
Conclusions 
In conclusion, we found that medication persistence was higher with BPH than OAB 
medications overall, whereas switching rates were higher in the OAB group. The lower 
persistence of OAB medication may be due to less efficacy or tolerability. The possibility of 
under treatment of OAB also warrants future investigations. 
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Table 1. OAB Subject Evaluation Table with Sample Sizes based on the Inclusion and 
Exclusion Criteria 
 
Subject Evaluation N % 
1. All patients enrolled for some time during Jul. 1, 2009 - Jun. 30, 2012 89,994,604 100.000 
2. (1) and female or male (excluding patients with unknown gender) 89,994,604 100.000 
3. (2) and with any OAB diagnosis during Jul. 1, 2009 - Jun. 30, 2012 2,947,100 3.275 
4. (3) and with 2+ OAB diagnosis at least 30 days apart 741,898 0.824 
5. (4) and without any OAB diagnosis during 12 months (360 days) pre-index 682,306 0.758 
6. (5) and with index and second immediate OAB diagnosis at least 30 days apart 531,285 0.590 
7. (6) and with continuous enrollment during 1 year (360 days) pre-index 258,015 0.287 
8. (7) and with continuous enrollment during 6 months (180 days) on or post-index 246,429 0.274 
9. (8) and with age 18+ 226,164 0.251 
10. (9) and excluding patients with any exclusion diagnosis during study period 160,853 0.179 
11.1. (10) and with follow-up days between 6-<24 months 68,150 0.076 
11.2. (10) and with follow-up days 24+ months 92,703 0.103 
12. (10) and with any OAB treatment medications on the index date or post-index 
and with only 1 type of OAB Rx on the earliest OAB Rx date 
38,909 0.043 
13.1. (12) and with follow-up days between 6-<24 months 13,855 0.015 
13.2. (12) and with follow-up days 24+ months 25,054 0.028 
 
 
 
*All percentages are relative to all patients enrolled, i.e. 89,994,604.  
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Table 2. BPH Subject Evaluation Table with Sample Sizes based on Inclusion and 
Exclusion Criteria 
 
Subject Evaluation  N % 
1. All patients enrolled for some time during Jul. 1, 2009 - Jun. 30, 2012  89,994,604 100.000 
2. (1) and male only 43,710,062 48.000 
3. (2) and with any Benign Prostatic Hypertrophy (BPH) diagnosis during Jul. 1, 
2009 - Jun. 30, 2012 
2,058,953 2.288 
4. (3) and with 2+ BPH diagnosis at least 30 days apart 888,875 0.988 
5. (4) and without any BPH diagnosis during 12 months (360 days) pre-index 767,605 0.853 
6. (5) and with index and second immediate BPH diagnosis at least 30 days apart 583,227 0.648 
7. (6) and with continuous enrollment during 1 year (360 days) pre-index 263,176 0.292 
8. (7) and with continuous enrollment during 6 months (180 days) on or post-index 254,163 0.282 
9. (8) and with age 18+ 253,817 0.282 
10. (9) and excluding patients with any exclusion diagnosis during study period 171,224 0.190 
11.1. (10) and with follow-up days between 6-<24 months 59,052 0.066 
11.2. (10) and with follow-up days 24+ months 112,172 0.125 
12. (10) and with any BPH treatment medications on the index date or post-index and 
with only 1 type of BPH Rx on the earliest BPH Rx date 
69,079 0.077 
13.1. (12) and with follow-up days between 6-<24 months 20,641 0.023 
13.2. (12) and with follow-up days 24+ months 48,438 0.054 
 
 
 
*All percentages are relative to all patients enrolled, i.e. 89,994,604.  
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Table 3. OAB Patients’ Baseline Demographics 
 
Baseline Demographic 
Characteristics 
  
Overall 
N = 
38,909 
Females 
N = 
31,701 
Females, 
18-64 
Years Old 
N = 
19,783 
Females, 
65+ Year 
Old 
N = 
11,918 
Males 
N = 
7,208 
Males, 
18-64 
Years 
Old 
N = 
3,480 
Males, 
65+ Year 
Old 
N = 
3,728 
Age 
Mean (Standard 
Deviation) 
61.73 
(15.25) 
60.92 
(15.22) 
51.41 
(9.85) 
76.71 
(7.47) 
65.31 
(14.87) 
52.84 
(10.22) 
76.95 
(7.02) 
Median 61.00 60.00 53.00 76.00 66.00 56.00 77.00 
Geographic Region 
Northeast Region 4,844 
(12.45%) 
3,725 
(11.75%) 
2,154 
(10.89%) 
1,571 
(13.18%) 
1,119 
(15.52%) 
525 
(15.09%) 
594 
(15.93%) 
North Central Region 11,245 
(28.90%) 
9,042 
(28.52%) 
5,372 
(27.15%) 
3,670 
(30.79%) 
2,203 
(30.56%) 
1,015 
(29.17%) 
1,188 
(31.87%) 
South Region 14,245 
(36.61%) 
11,881 
(37.48%) 
8,347 
(42.19%) 
3,534 
(29.65%) 
2,364 
(32.80%) 
1,267 
(36.41%) 
1,097 
(29.43%) 
West Region 8,274 
(21.27%) 
6,791 
(21.42%) 
3,691 
(18.66%) 
3,100 
(26.01%) 
1,483 
(20.57%) 
644 
(18.51%) 
839 
(22.51%) 
Unknown Region 301 
(0.77%) 
262 
(0.83%) 
219 
(1.11%) 
43 
(0.36%) 
39 
(0.54%) 
29 
(0.83%) 
10 
(0.27%) 
Insurance Plan 
Employer 29,148 
(74.91%) 
23,435 
(73.93%) 
13,138 
(66.41%) 
10,297 
(86.40%) 
5,713 
(79.26%) 
2,416 
(69.43%) 
3,297 
(88.44%) 
  
Health Plan 
9,761 
(25.09%) 
8,266 
(26.07%) 
6,645 
(33.59%) 
1,621 
(13.60%) 
1,495 
(20.74%) 
1,064 
(30.57%) 
431 
(11.56%) 
Type of Benefit Plan 
Missing/Unknown 944 
(2.43%) 
775 
(2.44%) 
553 
(2.80%) 
222 
(1.86%) 
169 
(2.34%) 
91 
(2.61%) 
78 
(2.09%) 
Comprehensive 8,879 
(22.82%) 
6,762 
(21.33%) 
966 
(4.88%) 
5,796 
(48.63%) 
2,117 
(29.37%) 
187 
(5.37%) 
1,930 
(51.77%) 
Exclusive Provider 
Organization (EPO) 
282 
(0.72%) 
233 
(0.73%) 
226 
(1.14%) 
7 (0.06%) 49 
(0.68%) 
46 
(1.32%) 
3 (0.08%) 
Health Maintenance 
Organization (HMO) 
6,518 
(16.75%) 
5,487 
(17.31%) 
3,696 
(18.68%) 
1,791 
(15.03%) 
1,031 
(14.30%) 
586 
(16.84%) 
445 
(11.94%) 
Point of Service 
(POS) 
2,525 
(6.49%) 
2,069 
(6.53%) 
1,657 
(8.38%) 
412 
(3.46%) 
456 
(6.33%) 
330 
(9.48%) 
126 
(3.38%) 
Preferred Provider 
Organization (PPO) 
18,355 
(47.17%) 
15,193 
(47.93%) 
11,516 
(58.21%) 
3,677 
(30.85%) 
3,162 
(43.87%) 
2,021 
(58.07%) 
1,141 
(30.61%) 
POS with Capitation 113 
(0.29%) 
87 
(0.27%) 
82 
(0.41%) 
5 (0.04%) 26 
(0.36%) 
24 
(0.69%) 
2 (0.05%) 
Consumer-Directed 
Health Plan (CDHP) 
984 
(2.53%) 
832 
(2.62%) 
828 
(4.19%) 
4 (0.03%) 152 
(2.11%) 
149 
(4.28%) 
3 (0.08%) 
High-Deductible 
Health Plan (HDHP) 
309 
(0.79%) 
263 
(0.83%) 
259 
(1.31%) 
4 (0.03%) 46 
(0.64%) 
46 
(1.32%) 
0 (0.00%) 
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Table 4. BPH Male Patients’ Baseline Demographics 
 
Baseline Demographic Characteristics 
  
Overall 
N = 69,079 
18-64 Years Old 
N = 36,336 
65+ Years Old 
N = 32,743 
Age 
Mean (Standard Deviation) 65.54 (11.12) 56.88 (5.88) 75.14 (6.88) 
Median 64.00 58.00 74.00 
Geographic Region 
Northeast Region 9,126 (13.21%) 4,426 (12.18%) 4,700 (14.35%) 
North Central Region 19,146 (27.72%) 8,928 (24.57%) 10,218 (31.21%) 
South Region 25,131 (36.38%) 15,155 (41.71%) 9,976 (30.47%) 
West Region 15,265 (22.10%) 7,524 (20.71%) 7,741 (23.64%) 
Unknown Region 411 (0.59%) 303 (0.83%) 108 (0.33%) 
Insurance Plan 
Employer 54,419 (78.78%) 25,556 (70.33%) 28,863 (88.15%) 
Health Plan 14,660 (21.22%) 10,780 (29.67%) 3,880 (11.85%) 
Type of Benefit Plan 
Missing/Unknown 1,662 (2.41%) 910 (2.50%) 752 (2.30%) 
Comprehensive 18,413 (26.65%) 2,245 (6.18%) 16,168 (49.38%) 
Exclusive Provider Organization (EPO) 511 (0.74%) 476 (1.31%) 35 (0.11%) 
Health Maintenance Organization (HMO) 10,719 (15.52%) 6,288 (17.31%) 4,431 (13.53%) 
Point of Service (POS) 4,160 (6.02%) 3,011 (8.29%) 1,149 (3.51%) 
Preferred Provider Organization (PPO) 31,382 (45.43%) 21,236 (58.44%) 10,146 (30.99%) 
POS with Capitation 225 (0.33%) 199 (0.55%) 26 (0.08%) 
Consumer-Directed Health Plan (CDHP) 1,519 (2.20%) 1,492 (4.11%) 27 (0.08%) 
High-Deductible Health Plan (HDHP) 488 (0.71%) 479 (1.32%) 9 (0.03%) 
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Table 5. Type of index OAB medication during the follow-up period. 
 
 Overall All Male Male 18-
64 Years 
Old 
Male 65+ 
Year Old 
All 
Female 
Female 
18-64 
Years Old 
Female 
65+ Year 
Old 
Index OAB 
medication 
N = 
38,909 
N = 7,208 N = 3,480 N = 3,728 N = 
31,701 
N = 
19,783 
N = 
11,918 
Darifenacin 3,227 
(8.29%) 
584 
(8.10%) 
234 
(6.72%) 
350 
(9.39%) 
2,643 
(8.34%) 
1,508 
(7.62%) 
1,135 
(9.52%) 
Fesoterodine 2,662 
(6.84%) 
527 
(7.31%) 
273 
(7.84%) 
254 
(6.81%) 
2,135 
(6.73%) 
1,360 
(6.87%) 
775 
(6.50%) 
Mirabegron 61 
(0.16%) 
14 
(0.19%) 
5 (0.14%) 9 (0.24%) 47 
(0.15%) 
23 
(0.12%) 
24 
(0.20%) 
Oxybutynin 12,896 
(33.14%) 
2,373 
(32.92%) 
1,155 
(33.19%) 
1,218 
(32.67%) 
10,523 
(33.19%) 
6,542 
(33.07%) 
3,981 
(33.40%) 
Solifenacin 11,726 
(30.14%) 
2,304 
(31.96%) 
1,205 
(34.63%) 
1,099 
(29.48%) 
9,422 
(29.72%) 
6,283 
(31.76%) 
3,139 
(26.34%) 
Tolterodine 6,802 
(17.48%) 
1,074 
(14.90%) 
492 
(14.14%) 
582 
(15.61%) 
5,728 
(18.07%) 
3,439 
(17.38%) 
2,289 
(19.21%) 
Trospium 1,535 
(3.95%) 
332 
(4.61%) 
116 
(3.33%) 
216 
(5.79%) 
1,203 
(3.79%) 
628 
(3.17%) 
575 
(4.82%) 
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Table 6. Type of index BPH medication during the follow-up 
 
  Overall 18-64 Years Old 65+ Years Old 
Index BPH medication N = 69,079 N = 36,336 N = 32,743 
Alfuzosin 4,035 (5.84%) 2,646 (7.28%) 1,389 (4.24%) 
Doxazosin 5,363 (7.76%) 2,786 (7.67%) 2,577 (7.87%) 
Dutasteride 6,894 (9.98%) 3,341 (9.19%) 3,553 (10.85%) 
Dutasteride/Tamsulosin 1,503 (2.18%) 889 (2.45%) 614 (1.88%) 
Finasteride 8,918 (12.91%) 3,627 (9.98%) 5,291 (16.16%) 
Mirabegron 24 (0.03%) 11 (0.03%) 13 (0.04%) 
Prazosin 256 (0.37%) 106 (0.29%) 150 (0.46%) 
Silodosin 2,120 (3.07%) 1,382 (3.80%) 738 (2.25%) 
Tamsulosin 33,472 (48.45%) 18,432 (50.73%) 15,040 (45.93%) 
Terazosin 6,494 (9.40%) 3,116 (8.58%) 3,378 (10.32%) 
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Table 7. OAB and BPH Treatment Usage Patterns during the Follow-up Period 
 
OAB 
Medications 
Overall 
N=38,909 
Males 
N=7,208 
Males 
18-64 
Years 
N=3,480 
Males 
65+ Years 
N=3,728 
Females 
N=31,701 
Females  
18-64 
Years 
N=19,783 
Females  
65+ Years  
N=11,918 
Continued 13,098 
(33.66%) 
2,538 
(35.21%) 
1,131 
(32.50%) 
1,407 
(37.74%) 
10,560 
(33.31%) 
6,364 
(32.17%) 
4,196 
(35.21%) 
Discontinued 22,169 
(56.98%) 
4,074 
(56.52%) 
2,078 
(59.71%) 
1,996 
(53.54%) 
18,095 
(57.08%) 
11,565 
(58.46%) 
6,530 
(54.79%) 
Switched 3,642 
(9.36%) 
596 
(8.27%) 
271 
(7.79%) 
325 
(8.72%) 
3,046 
(9.61%) 
1,854 
(9.37%) 
1,192 
(10.00%) 
 
BPH 
Medications 
Overall  
(Males 
only) 
N=69,079 
Males 
N=69,079 
Males 
18-64 
Years 
N=36,336 
Males 
65+ Years 
N=32,743 
N/A N/A N/A 
Continued 38,762 
(56.11%) 
38,762 
(56.11%) 
18,600 
(51.19%) 
20,162 
(61.58%) 
N/A N/A N/A 
Discontinued 25,585 
(37.04%) 
25,585 
(37.04%) 
15,102 
(41.56%) 
10,483 
(32.02%) 
N/A N/A N/A 
Switched 4,732 
(6.85%) 
4,732 
(6.85%) 
2,634 
(7.25%) 
2,098 
(6.41%) 
N/A N/A N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
